董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Grady Grant, III | 男 | Independent Director | 70 | 8.90万美元 | 0.12 | 2026-08-21 |
| Barbara Lopez Kunz | 女 | Independent Director | 68 | 9.65万美元 | 0.04 | 2026-08-21 |
| Jeffrey G. Lamothe | 男 | Chief Executive Officer,Director and President | 60 | 102.02万美元 | 0.10 | 2026-08-21 |
| Zsolt Harsanyi | 男 | Independent Director | 82 | 11.15万美元 | 0.04 | 2026-08-21 |
| Marvin L. White | 男 | Director and Executive Chair | 64 | 127.74万美元 | 0.13 | 2026-08-21 |
| Daniel J. Abdun Nabi | 男 | Independent Director | 71 | 9.15万美元 | 0.04 | 2026-08-21 |
| John E. Niederhuber | 男 | Lead Independent Director | 87 | 10.85万美元 | 0.04 | 2026-08-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey G. Lamothe | 男 | Chief Executive Officer,Director and President | 60 | 102.02万美元 | 0.10 | 2026-08-21 |
| SoYoung Kwon | 女 | General Counsel, Business Development and Corporate Affairs and Senior Vice President | 57 | 90.45万美元 | 0.06 | 2026-08-21 |
| Dirk Huebner | 男 | Chief Medical Officer and Senior Vice President | 63 | 未披露 | 未持股 | 2026-08-21 |
| Mary Janatpour | 女 | Chief Scientific Officer and Senior Vice President | 59 | 未披露 | 未持股 | 2026-08-21 |
| Marvin L. White | 男 | Director and Executive Chair | 64 | 127.74万美元 | 0.13 | 2026-08-21 |
| Daphne Taylor | 女 | Chief Financial Officer and Senior Vice President | 59 | 未披露 | 未持股 | 2026-08-21 |
董事简历
中英对照 | 中文 | 英文- Grady Grant, III
-
Grady Grant, III目前担任Vanigent BioPharm的执行副总裁/合伙人，在2022年4月之前，他是Evolve Biosystems的高级副总裁，Evolve Biosystems是一家生物技术公司，专门提供基于微生物组的产品，以维持健康的新生儿肠道微生物组。此前，2020年至2021年，他担任New Vision Pharmaceuticals LLC的临时首席商务官，该公司是一家专注于吹气填充密封包装的合同药品开发和制造公司；2018年至2020年，他担任再生医学公司Tissue Tech Limited的销售副总裁；2011年至2018年，他担任专注于儿科营养的上市公司美赞臣营养品有限公司的医疗销售副总裁。在此之前，他曾在礼来公司服务了30年，担任过各种职务，包括2006年至2011年担任销售神经科学副总裁。格兰特先生在天普大学获得了药学学士学位。格兰特先生还被美国国家公司董事协会认证为董事会董事。
Grady Grant, III currently serving as EVP/Partner of Vanigent BioPharm, and until April 2022, was Senior Vice President of Evolve Biosystems, a biotechnology company that specializes in providing microbiome based products to maintain a healthy newborn gut microbiome. Previously, from 2020 to 2021, he was Interim Chief Commercial Officer for New Vision Pharmaceuticals LLC, a contract pharmaceutical development and manufacturing company specializing in blow fill seal packaging, from 2018 to 2020, he was the Vice President of Sales for Tissue Tech Limited, a regenerative medicine company, and from 2011 to 2018, he worked as Vice President of Medical Sales for Mead Johnson Nutrition Company, a public company focused on pediatric nutrition. Prior to that, he served for 30 years at Eli Lilly and Company in various capacities, including service as Vice President of Sales Neuroscience from 2006 to 2011. Mr. Grant earned a bachelor degree in pharmaceutical science from Temple University. Mr. Grant is also certified as a Board Director by the National Association of Corporate Directors. - Grady Grant, III目前担任Vanigent BioPharm的执行副总裁/合伙人，在2022年4月之前，他是Evolve Biosystems的高级副总裁，Evolve Biosystems是一家生物技术公司，专门提供基于微生物组的产品，以维持健康的新生儿肠道微生物组。此前，2020年至2021年，他担任New Vision Pharmaceuticals LLC的临时首席商务官，该公司是一家专注于吹气填充密封包装的合同药品开发和制造公司；2018年至2020年，他担任再生医学公司Tissue Tech Limited的销售副总裁；2011年至2018年，他担任专注于儿科营养的上市公司美赞臣营养品有限公司的医疗销售副总裁。在此之前，他曾在礼来公司服务了30年，担任过各种职务，包括2006年至2011年担任销售神经科学副总裁。格兰特先生在天普大学获得了药学学士学位。格兰特先生还被美国国家公司董事协会认证为董事会董事。
- Grady Grant, III currently serving as EVP/Partner of Vanigent BioPharm, and until April 2022, was Senior Vice President of Evolve Biosystems, a biotechnology company that specializes in providing microbiome based products to maintain a healthy newborn gut microbiome. Previously, from 2020 to 2021, he was Interim Chief Commercial Officer for New Vision Pharmaceuticals LLC, a contract pharmaceutical development and manufacturing company specializing in blow fill seal packaging, from 2018 to 2020, he was the Vice President of Sales for Tissue Tech Limited, a regenerative medicine company, and from 2011 to 2018, he worked as Vice President of Medical Sales for Mead Johnson Nutrition Company, a public company focused on pediatric nutrition. Prior to that, he served for 30 years at Eli Lilly and Company in various capacities, including service as Vice President of Sales Neuroscience from 2006 to 2011. Mr. Grant earned a bachelor degree in pharmaceutical science from Temple University. Mr. Grant is also certified as a Board Director by the National Association of Corporate Directors.
- Barbara Lopez Kunz
-
Barbara Lopez Kunz目前在临床研究机构Caidya担任首席执行官。Kunz女士于2023年3月底退休，担任非营利性医疗保健公司药物信息协会的总裁兼全球首席执行官。Kunz女士在专科诊断领军企业维尔芬董事会担任董事、儿童National Health体系研究院董事会副主席，自2022年起在彩雅股份董事会任职。2007年至2013年，她在私营非营利性应用科学技术开发公司Battelle Memorial Institute担任健康和生命科学全球业务总裁。在此之前，她曾于2003年至2007年在赛默飞世尔科技公司旗下Fisher Biosciences担任执行副总裁/总经理，并于2000年至2003年在Uniqema领导拉丁美洲区域业务，该公司于2006年被Croda International plc收购。Kunz女士还曾于1997年至1998年担任杜邦公司战略/并购主管，并于1993年至1997年担任帝国化学工业公司（现为阿斯利康/禾大）企业业务集团全球副总裁。Kunz女士在泰尔学院获得生物和化学学士学位，在克利夫兰州立大学获得MBA课程作业，在阿克伦大学获得高分子科学硕士学位，并在欧洲工商管理学院的国际高管课程中获得认证。她还被美国国家公司董事协会认证为董事会董事。
Barbara Lopez Kunz is currently serving as Chief Executive Officer at Caidya, a clinical research organization. Ms. Kunz retired as President and Global Chief Executive Officer of the Drug Information Association, a non profit health care company, at the end of March 2023. Ms. Kunz serves as a director on the board of Werfen, a leader in specialized diagnostics, as Vice Chair of the Board of Directors of Children's National Health System Research Institute, and has served on the Board of Directors of Caidya since 2022. From 2007 to 2013, she worked as President of Health and Life Sciences Global Business at Battelle Memorial Institute, a private nonprofit applied science and technology development company. Prior to that, she worked as Executive VP/GM for Thermo Fisher Scientific Inc.'s Fisher Biosciences from 2003 to 2007 and led the Latin America regional business from 2000 to 2003 at Uniqema, a company acquired by Croda International plc in 2006. Ms. Kunz also worked as Head of Strategy/M&A of Dupont from 1997 to 1998 and was the Global VP for the Enterprise Business Group of Imperial Chemical Industries (now AstraZeneca/Croda) from 1993 to 1997. Ms. Kunz earned bachelor degrees in both biology and chemistry from Thiel College, MBA coursework at Cleveland State University, an MS in polymer science from the University of Akron and is certified in INSEAD's international executive program. She is also certified as a Board Director by the National Association of Corporate Directors. - Barbara Lopez Kunz目前在临床研究机构Caidya担任首席执行官。Kunz女士于2023年3月底退休，担任非营利性医疗保健公司药物信息协会的总裁兼全球首席执行官。Kunz女士在专科诊断领军企业维尔芬董事会担任董事、儿童National Health体系研究院董事会副主席，自2022年起在彩雅股份董事会任职。2007年至2013年，她在私营非营利性应用科学技术开发公司Battelle Memorial Institute担任健康和生命科学全球业务总裁。在此之前，她曾于2003年至2007年在赛默飞世尔科技公司旗下Fisher Biosciences担任执行副总裁/总经理，并于2000年至2003年在Uniqema领导拉丁美洲区域业务，该公司于2006年被Croda International plc收购。Kunz女士还曾于1997年至1998年担任杜邦公司战略/并购主管，并于1993年至1997年担任帝国化学工业公司（现为阿斯利康/禾大）企业业务集团全球副总裁。Kunz女士在泰尔学院获得生物和化学学士学位，在克利夫兰州立大学获得MBA课程作业，在阿克伦大学获得高分子科学硕士学位，并在欧洲工商管理学院的国际高管课程中获得认证。她还被美国国家公司董事协会认证为董事会董事。
- Barbara Lopez Kunz is currently serving as Chief Executive Officer at Caidya, a clinical research organization. Ms. Kunz retired as President and Global Chief Executive Officer of the Drug Information Association, a non profit health care company, at the end of March 2023. Ms. Kunz serves as a director on the board of Werfen, a leader in specialized diagnostics, as Vice Chair of the Board of Directors of Children's National Health System Research Institute, and has served on the Board of Directors of Caidya since 2022. From 2007 to 2013, she worked as President of Health and Life Sciences Global Business at Battelle Memorial Institute, a private nonprofit applied science and technology development company. Prior to that, she worked as Executive VP/GM for Thermo Fisher Scientific Inc.'s Fisher Biosciences from 2003 to 2007 and led the Latin America regional business from 2000 to 2003 at Uniqema, a company acquired by Croda International plc in 2006. Ms. Kunz also worked as Head of Strategy/M&A of Dupont from 1997 to 1998 and was the Global VP for the Enterprise Business Group of Imperial Chemical Industries (now AstraZeneca/Croda) from 1993 to 1997. Ms. Kunz earned bachelor degrees in both biology and chemistry from Thiel College, MBA coursework at Cleveland State University, an MS in polymer science from the University of Akron and is certified in INSEAD's international executive program. She is also certified as a Board Director by the National Association of Corporate Directors.
- Jeffrey G. Lamothe
-
Jeffrey G. Lamothe曾在Aptevo Therapeutics Inc.董事会任职，自2026年4月起担任公司总裁兼首席执行官。Lamothe先生于2023年3月至2026年4月期间担任公司执行副总裁兼首席运营官，此前自2022年2月起担任执行副总裁兼首席财务官，此前自2016年7月起担任高级副总裁兼首席财务官。Lamothe先生此前曾担任Emergent生物科学部门财务副总裁。Lamothe先生于2014年2月在Emergent完成对Cangene Corporation（“Cangene”）的收购时担任这一职务，他在该公司担任首席财务官。Lamothe先生于2012年8月开始担任Cangene的首席财务官。在此之前，Lamothe先生是Smith Carter Architects and Engineers Incorporated的首席财务官，该职位于2010年1月至2012年7月担任。此前，他还在Kitchen Craft Cabinetry担任总裁兼首席执行官，此前他曾在该机构担任财务副总裁兼首席财务官。Lamothe先生过去的其他经验包括担任Motor Coach Industries的首席财务官，Lamothe先生曾在James Richardson父子有限公司和安永会计师事务所担任过不同职务。Lamothe先生在马尼托巴大学获得商业学士（荣誉）学位，是一名特许公共会计师。
Jeffrey G. Lamothe has served on Aptevo Therapeutics Inc.'s Board and served as the President and Chief Executive Officer of the Company since April 2026. Mr. Lamothe served as the Company's Executive Vice President and Chief Operating Officer from March 2023 to April 2026, previously as Executive Vice President and Chief Financial Officer since February 2022 and previously as Senior Vice President and Chief Financial Officer since July 2016. Mr. Lamothe previously served as Emergent's Vice President Finance, Biosciences Division. Mr. Lamothe assumed this role in February 2014 when Emergent concluded the acquisition of Cangene Corporation ("Cangene"), where he was Chief Financial Officer. Mr. Lamothe assumed the role of Chief Financial Officer of Cangene in August 2012. Prior to that, Mr. Lamothe was the Chief Financial Officer for Smith Carter Architects and Engineers Incorporated, a position which he held from January 2010 until July 2012. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry after occupying the position of VP Finance and Chief Financial Officer with that organization. Mr. Lamothe's other past experience includes serving as Chief Financial Officer for Motor Coach Industries, and Mr. Lamothe has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP. Mr. Lamothe earned his Bachelor of Commerce (honors) degree from the University of Manitoba and is a Chartered Public Accountant. - Jeffrey G. Lamothe曾在Aptevo Therapeutics Inc.董事会任职，自2026年4月起担任公司总裁兼首席执行官。Lamothe先生于2023年3月至2026年4月期间担任公司执行副总裁兼首席运营官，此前自2022年2月起担任执行副总裁兼首席财务官，此前自2016年7月起担任高级副总裁兼首席财务官。Lamothe先生此前曾担任Emergent生物科学部门财务副总裁。Lamothe先生于2014年2月在Emergent完成对Cangene Corporation（“Cangene”）的收购时担任这一职务，他在该公司担任首席财务官。Lamothe先生于2012年8月开始担任Cangene的首席财务官。在此之前，Lamothe先生是Smith Carter Architects and Engineers Incorporated的首席财务官，该职位于2010年1月至2012年7月担任。此前，他还在Kitchen Craft Cabinetry担任总裁兼首席执行官，此前他曾在该机构担任财务副总裁兼首席财务官。Lamothe先生过去的其他经验包括担任Motor Coach Industries的首席财务官，Lamothe先生曾在James Richardson父子有限公司和安永会计师事务所担任过不同职务。Lamothe先生在马尼托巴大学获得商业学士（荣誉）学位，是一名特许公共会计师。
- Jeffrey G. Lamothe has served on Aptevo Therapeutics Inc.'s Board and served as the President and Chief Executive Officer of the Company since April 2026. Mr. Lamothe served as the Company's Executive Vice President and Chief Operating Officer from March 2023 to April 2026, previously as Executive Vice President and Chief Financial Officer since February 2022 and previously as Senior Vice President and Chief Financial Officer since July 2016. Mr. Lamothe previously served as Emergent's Vice President Finance, Biosciences Division. Mr. Lamothe assumed this role in February 2014 when Emergent concluded the acquisition of Cangene Corporation ("Cangene"), where he was Chief Financial Officer. Mr. Lamothe assumed the role of Chief Financial Officer of Cangene in August 2012. Prior to that, Mr. Lamothe was the Chief Financial Officer for Smith Carter Architects and Engineers Incorporated, a position which he held from January 2010 until July 2012. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry after occupying the position of VP Finance and Chief Financial Officer with that organization. Mr. Lamothe's other past experience includes serving as Chief Financial Officer for Motor Coach Industries, and Mr. Lamothe has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP. Mr. Lamothe earned his Bachelor of Commerce (honors) degree from the University of Manitoba and is a Chartered Public Accountant.
- Zsolt Harsanyi
-
Zsolt Harsanyi自2004年8月，一直担任公司董事。自2011年3月以来，他曾任N-Gene Research Laboratories, Inc董事会主席，这是一家私人持有的生物制药公司。在此之前，从2004年12月至2011年2月，他担任Exponential Biotherapies 首席执行官及董事会主席，这是一家私人生物技术公司的。从1983年1月至2004年12月，他担任Porton International plc总裁，这是制药和疫苗的公司。他是Dynport Vaccine 公司创始人，公司创办于1996年9月。在加盟Porton International之前，他是E.F. Hutton企业融资副总裁。在此之前，他带领美国国会技术评估办公室生物技术第一评估，担任总裁委员会在医学和生物医学和行为研究伦理问题研究方面的顾问，他还是康奈尔大学医学院对微生物学和遗传学学院任职。他获得 Albert Einstein 医学院博士学位， Amherst 学院学士学位。
Zsolt Harsanyi has served on the Board of Directors of Emergent since 2004 and as its Chairman since April 1, 2022 and as Chairman of the Board of Directors of N Gene Research Laboratories, Inc., a privately held biotechnology company, since 2011. Prior to that, Dr. Harsanyi served as Chief Executive Officer and Chairman of the Board of Directors of Exponential Biotherapies Inc., a private biotechnology company, from 2004 to 2011. Prior to that, Dr. Harsanyi served as President of Porton International Inc., a pharmaceutical and vaccine company, from January 1983 to December 2004. In 1996, Dr. Harsanyi founded Dynport Vaccine Company LLC. Prior to that, he was Vice President of Corporate Finance at E.F. Hutton, Inc. Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress' Office of Technology Assessment, served as a consultant to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell Medical College. Dr. Harsanyi received his bachelor's degree from Amherst College and his Ph.D. in genetics from Albert Einstein College of Medicine. - Zsolt Harsanyi自2004年8月，一直担任公司董事。自2011年3月以来，他曾任N-Gene Research Laboratories, Inc董事会主席，这是一家私人持有的生物制药公司。在此之前，从2004年12月至2011年2月，他担任Exponential Biotherapies 首席执行官及董事会主席，这是一家私人生物技术公司的。从1983年1月至2004年12月，他担任Porton International plc总裁，这是制药和疫苗的公司。他是Dynport Vaccine 公司创始人，公司创办于1996年9月。在加盟Porton International之前，他是E.F. Hutton企业融资副总裁。在此之前，他带领美国国会技术评估办公室生物技术第一评估，担任总裁委员会在医学和生物医学和行为研究伦理问题研究方面的顾问，他还是康奈尔大学医学院对微生物学和遗传学学院任职。他获得 Albert Einstein 医学院博士学位， Amherst 学院学士学位。
- Zsolt Harsanyi has served on the Board of Directors of Emergent since 2004 and as its Chairman since April 1, 2022 and as Chairman of the Board of Directors of N Gene Research Laboratories, Inc., a privately held biotechnology company, since 2011. Prior to that, Dr. Harsanyi served as Chief Executive Officer and Chairman of the Board of Directors of Exponential Biotherapies Inc., a private biotechnology company, from 2004 to 2011. Prior to that, Dr. Harsanyi served as President of Porton International Inc., a pharmaceutical and vaccine company, from January 1983 to December 2004. In 1996, Dr. Harsanyi founded Dynport Vaccine Company LLC. Prior to that, he was Vice President of Corporate Finance at E.F. Hutton, Inc. Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress' Office of Technology Assessment, served as a consultant to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell Medical College. Dr. Harsanyi received his bachelor's degree from Amherst College and his Ph.D. in genetics from Albert Einstein College of Medicine.
- Marvin L. White
-
Marvin L. White，目前担任董事的任期始于2020年10月。White先生曾担任Aptevo Therapeutics Inc.（“Aptevo”）的总裁兼首席执行官，并自2016年8月起担任其董事会成员。White先生于2010年6月首次担任Emergent的董事，直到2016年5月从Emergent董事会辞职。在加入Aptevo之前，他还曾担任Emergent的顾问。从2008年到2014年3月，White先生担任St. Vincent Health的首席财务官，负责所有19家医院和36家合资企业的财务、材料管理、会计、患者财务服务和管理式医疗。在2008年加入St. Vincent Health之前，White先生是Lilly USA（礼来公司的子公司）的首席财务官，他还曾在该公司的企业战略集团担任财务和企业融资以及投资银行方面的领导职务。怀特先生是OneAmerica Financial Insurance Partners，Inc.的董事，该公司是一家位于印第安纳州印第安纳波利斯的相互保险和金融服务公司，也是一家位于西雅图的牙科保险公司Delta Dental of Washington。从2014年6月到2016年8月，White先生在Washington Prime Group的董事会任职，这是一家投资于购物中心的NYSE REIT。从2015年7月到2017年3月，怀特先生在上市制药公司CoLucid Pharmaceuticals，Inc.的董事会任职。White先生获得了威尔伯福斯大学会计学学士学位和印第安纳大学金融硕士学位。
Marvin L. White has served as a member of Aptevo Therapeutics Inc.'s Board since August 2016 and served as Aptevo Therapeutics Inc.'s Executive Chair since April 2026. Mr. White served as Aptevo Therapeutics Inc.'s President and Chief Executive Officer from August 2016 to April 2026. From 2010 to 2016, Mr. White served as a director of Emergent, and in 2020, he rejoined the Emergent Board of Directors. From 2008 to 2014, Mr. White served as the Chief Financial Officer of St. Vincent Health, and was responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was the Chief Financial Officer of Lilly USA, LLC, a subsidiary of Eli Lilly and Company, where he also held leadership positions in treasury and corporate finance and investment banking in the Corporate Strategy Group. He serves on the Board of Directors of OneAmerica Financial Insurance Partners, Inc., a mutual insurance and financial services company based in Indianapolis, Indiana and Delta Dental of Washington, a non profit company. Prior to taking the role of President and Chief Executive Officer of Aptevo, Mr. White served on the Board of Directors of Washington Prime Group, a New York Stock Exchange listed real estate investment trust (REIT) that invests in shopping centers, and CoLucid Pharmaceuticals, Inc., a pharmaceutical company that was publicly traded until its acquisition by Eli Lilly in 2017. Mr. White earned a bachelor of science degree from Wilberforce University in Accounting and his MBA degree in Finance from Indiana University. - Marvin L. White，目前担任董事的任期始于2020年10月。White先生曾担任Aptevo Therapeutics Inc.（“Aptevo”）的总裁兼首席执行官，并自2016年8月起担任其董事会成员。White先生于2010年6月首次担任Emergent的董事，直到2016年5月从Emergent董事会辞职。在加入Aptevo之前，他还曾担任Emergent的顾问。从2008年到2014年3月，White先生担任St. Vincent Health的首席财务官，负责所有19家医院和36家合资企业的财务、材料管理、会计、患者财务服务和管理式医疗。在2008年加入St. Vincent Health之前，White先生是Lilly USA（礼来公司的子公司）的首席财务官，他还曾在该公司的企业战略集团担任财务和企业融资以及投资银行方面的领导职务。怀特先生是OneAmerica Financial Insurance Partners，Inc.的董事，该公司是一家位于印第安纳州印第安纳波利斯的相互保险和金融服务公司，也是一家位于西雅图的牙科保险公司Delta Dental of Washington。从2014年6月到2016年8月，White先生在Washington Prime Group的董事会任职，这是一家投资于购物中心的NYSE REIT。从2015年7月到2017年3月，怀特先生在上市制药公司CoLucid Pharmaceuticals，Inc.的董事会任职。White先生获得了威尔伯福斯大学会计学学士学位和印第安纳大学金融硕士学位。
- Marvin L. White has served as a member of Aptevo Therapeutics Inc.'s Board since August 2016 and served as Aptevo Therapeutics Inc.'s Executive Chair since April 2026. Mr. White served as Aptevo Therapeutics Inc.'s President and Chief Executive Officer from August 2016 to April 2026. From 2010 to 2016, Mr. White served as a director of Emergent, and in 2020, he rejoined the Emergent Board of Directors. From 2008 to 2014, Mr. White served as the Chief Financial Officer of St. Vincent Health, and was responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was the Chief Financial Officer of Lilly USA, LLC, a subsidiary of Eli Lilly and Company, where he also held leadership positions in treasury and corporate finance and investment banking in the Corporate Strategy Group. He serves on the Board of Directors of OneAmerica Financial Insurance Partners, Inc., a mutual insurance and financial services company based in Indianapolis, Indiana and Delta Dental of Washington, a non profit company. Prior to taking the role of President and Chief Executive Officer of Aptevo, Mr. White served on the Board of Directors of Washington Prime Group, a New York Stock Exchange listed real estate investment trust (REIT) that invests in shopping centers, and CoLucid Pharmaceuticals, Inc., a pharmaceutical company that was publicly traded until its acquisition by Eli Lilly in 2017. Mr. White earned a bachelor of science degree from Wilberforce University in Accounting and his MBA degree in Finance from Indiana University.
- Daniel J. Abdun Nabi
-
自2012年4月起，Daniel J. Abdun Nabi一直担任公司总裁兼首席执行官。2007年5月至2012年3月，他曾担任公司总裁兼首席运营官。从2004年12月至2008年1月，他曾担任公司秘书。2004年5月至2004年12月，任副总裁兼总法律顾问。1999年9月至2004年5月，他曾担任IGEN国际公司总法律顾问，这是一家生物技术公司，它的接班公司是BioVeris公司。在加盟IGEN之前，他曾担任North American Vaccine的法律事务高级副总裁，法律总顾问和秘书。他获得乔治敦大学法律中心税务法硕士学位，圣迭戈学院大学法学博士学位，马萨诸塞大学阿姆赫斯特分校政治学学士学位。
Daniel J. Abdun Nabi served as the President and Chief Executive Officer of Emergent from 2012 to 2019 and as a director of Emergent from 2009 to 2019. Prior to that, Mr. Abdun Nabi served in other various leadership positions at Emergent, including President and Chief Operating Officer from 2007 to 2012, Corporate Secretary from 2004 to 2008, Senior Vice President, Corporate Affairs and General Counsel from 2004 to 2007, and Vice President and General Counsel from May 2004 to December 2004. Before joining Emergent, Mr. Abdun Nabi was General Counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from 1999 to 2004, and Senior Vice President, Legal Affairs, General Counsel and Secretary of North American Vaccine, Inc., a publicly traded vaccine company acquired by Baxter International Inc. In 2000. Mr. Abdun Nabi earned a bachelor's degree in political science from the University of Massachusetts Amherst, a J.D. from the University of San Diego School of Law and an LLM from Georgetown University Law Center. - 自2012年4月起，Daniel J. Abdun Nabi一直担任公司总裁兼首席执行官。2007年5月至2012年3月，他曾担任公司总裁兼首席运营官。从2004年12月至2008年1月，他曾担任公司秘书。2004年5月至2004年12月，任副总裁兼总法律顾问。1999年9月至2004年5月，他曾担任IGEN国际公司总法律顾问，这是一家生物技术公司，它的接班公司是BioVeris公司。在加盟IGEN之前，他曾担任North American Vaccine的法律事务高级副总裁，法律总顾问和秘书。他获得乔治敦大学法律中心税务法硕士学位，圣迭戈学院大学法学博士学位，马萨诸塞大学阿姆赫斯特分校政治学学士学位。
- Daniel J. Abdun Nabi served as the President and Chief Executive Officer of Emergent from 2012 to 2019 and as a director of Emergent from 2009 to 2019. Prior to that, Mr. Abdun Nabi served in other various leadership positions at Emergent, including President and Chief Operating Officer from 2007 to 2012, Corporate Secretary from 2004 to 2008, Senior Vice President, Corporate Affairs and General Counsel from 2004 to 2007, and Vice President and General Counsel from May 2004 to December 2004. Before joining Emergent, Mr. Abdun Nabi was General Counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from 1999 to 2004, and Senior Vice President, Legal Affairs, General Counsel and Secretary of North American Vaccine, Inc., a publicly traded vaccine company acquired by Baxter International Inc. In 2000. Mr. Abdun Nabi earned a bachelor's degree in political science from the University of Massachusetts Amherst, a J.D. from the University of San Diego School of Law and an LLM from Georgetown University Law Center.
- John E. Niederhuber
-
John E. Niederhuber自2010年8月起曾担任董事。从2005年到2010年，任National Cancer Institute， 或NCI董事。他于2010年8月加盟Inova Health System，担任Inova研究所转化研究和个体化用药的执行副总裁兼首席执行官。他也是NCI的癌症研究中心辅助研究者，在肿瘤微环境导致增加的恶性学因素进行研究。他目前担任Novelos Therapeutics董事。在加入NCI前，从1997年到2005年，他是威斯康辛综合癌症中心的董事，威斯康辛医学院麦卡德尔实验室外科和肿瘤员的教授。1991年至1997年，任斯坦福大学外科院长。1987年至1991年，任约翰霍普金斯大学医学院教授，并从1973年到1987年，任密歇根大学教授。他毕业于西弗吉尼亚州贝瑟尼学院和俄亥俄州立大学医学院。他在密歇根大学进行外科实习。
John E. Niederhuber served as Aptevo Therapeutics Inc.'s Chairman (previously Vice Chairman and Lead Independent Director) from August 2016 to April 2026. Dr. Niederhuber is currently an adjunct professor of surgery and oncology at The Johns Hopkins University School of Medicine. Dr. Niederhuber is the former Executive Vice President of the Inova Health System, Founder of the Inova Translational Medicine Institute (Inova), and founding President and Chief Executive Officer of the Genomics and Bioinformatics Research Institute, a joint venture between Inova and the University of Virginia. Dr. Niederhuber joined the Inova Health System in 2010 as Executive Vice President of the Health System and Chief Executive Officer of Inova. He officially retired from his position at Inova in 2019. Prior to Inova, he served as the Director of the National Cancer Institute, the National Institutes of Health from 2006 to 2010 and as the Director of the University of Wisconsin Comprehensive Cancer Center and professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine from 1997 to 2005. He chaired the Department of Surgery at Stanford University School of Medicine from 1991 to 1997 and held professorships at The Johns Hopkins University School of Medicine from 1987 to 1991 and at the University of Michigan from 1973 to 1987. Dr. Niederhuber also previously served on the Board of Directors of Emergent from 2010 to 2016. Dr. Niederhuber earned a bachelor of science from Bethany College and his M.D. from The Ohio State University School of Medicine. - John E. Niederhuber自2010年8月起曾担任董事。从2005年到2010年，任National Cancer Institute， 或NCI董事。他于2010年8月加盟Inova Health System，担任Inova研究所转化研究和个体化用药的执行副总裁兼首席执行官。他也是NCI的癌症研究中心辅助研究者，在肿瘤微环境导致增加的恶性学因素进行研究。他目前担任Novelos Therapeutics董事。在加入NCI前，从1997年到2005年，他是威斯康辛综合癌症中心的董事，威斯康辛医学院麦卡德尔实验室外科和肿瘤员的教授。1991年至1997年，任斯坦福大学外科院长。1987年至1991年，任约翰霍普金斯大学医学院教授，并从1973年到1987年，任密歇根大学教授。他毕业于西弗吉尼亚州贝瑟尼学院和俄亥俄州立大学医学院。他在密歇根大学进行外科实习。
- John E. Niederhuber served as Aptevo Therapeutics Inc.'s Chairman (previously Vice Chairman and Lead Independent Director) from August 2016 to April 2026. Dr. Niederhuber is currently an adjunct professor of surgery and oncology at The Johns Hopkins University School of Medicine. Dr. Niederhuber is the former Executive Vice President of the Inova Health System, Founder of the Inova Translational Medicine Institute (Inova), and founding President and Chief Executive Officer of the Genomics and Bioinformatics Research Institute, a joint venture between Inova and the University of Virginia. Dr. Niederhuber joined the Inova Health System in 2010 as Executive Vice President of the Health System and Chief Executive Officer of Inova. He officially retired from his position at Inova in 2019. Prior to Inova, he served as the Director of the National Cancer Institute, the National Institutes of Health from 2006 to 2010 and as the Director of the University of Wisconsin Comprehensive Cancer Center and professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine from 1997 to 2005. He chaired the Department of Surgery at Stanford University School of Medicine from 1991 to 1997 and held professorships at The Johns Hopkins University School of Medicine from 1987 to 1991 and at the University of Michigan from 1973 to 1987. Dr. Niederhuber also previously served on the Board of Directors of Emergent from 2010 to 2016. Dr. Niederhuber earned a bachelor of science from Bethany College and his M.D. from The Ohio State University School of Medicine.
高管简历
中英对照 | 中文 | 英文- Jeffrey G. Lamothe
Jeffrey G. Lamothe曾在Aptevo Therapeutics Inc.董事会任职，自2026年4月起担任公司总裁兼首席执行官。Lamothe先生于2023年3月至2026年4月期间担任公司执行副总裁兼首席运营官，此前自2022年2月起担任执行副总裁兼首席财务官，此前自2016年7月起担任高级副总裁兼首席财务官。Lamothe先生此前曾担任Emergent生物科学部门财务副总裁。Lamothe先生于2014年2月在Emergent完成对Cangene Corporation（“Cangene”）的收购时担任这一职务，他在该公司担任首席财务官。Lamothe先生于2012年8月开始担任Cangene的首席财务官。在此之前，Lamothe先生是Smith Carter Architects and Engineers Incorporated的首席财务官，该职位于2010年1月至2012年7月担任。此前，他还在Kitchen Craft Cabinetry担任总裁兼首席执行官，此前他曾在该机构担任财务副总裁兼首席财务官。Lamothe先生过去的其他经验包括担任Motor Coach Industries的首席财务官，Lamothe先生曾在James Richardson父子有限公司和安永会计师事务所担任过不同职务。Lamothe先生在马尼托巴大学获得商业学士（荣誉）学位，是一名特许公共会计师。
Jeffrey G. Lamothe has served on Aptevo Therapeutics Inc.'s Board and served as the President and Chief Executive Officer of the Company since April 2026. Mr. Lamothe served as the Company's Executive Vice President and Chief Operating Officer from March 2023 to April 2026, previously as Executive Vice President and Chief Financial Officer since February 2022 and previously as Senior Vice President and Chief Financial Officer since July 2016. Mr. Lamothe previously served as Emergent's Vice President Finance, Biosciences Division. Mr. Lamothe assumed this role in February 2014 when Emergent concluded the acquisition of Cangene Corporation ("Cangene"), where he was Chief Financial Officer. Mr. Lamothe assumed the role of Chief Financial Officer of Cangene in August 2012. Prior to that, Mr. Lamothe was the Chief Financial Officer for Smith Carter Architects and Engineers Incorporated, a position which he held from January 2010 until July 2012. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry after occupying the position of VP Finance and Chief Financial Officer with that organization. Mr. Lamothe's other past experience includes serving as Chief Financial Officer for Motor Coach Industries, and Mr. Lamothe has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP. Mr. Lamothe earned his Bachelor of Commerce (honors) degree from the University of Manitoba and is a Chartered Public Accountant.- Jeffrey G. Lamothe曾在Aptevo Therapeutics Inc.董事会任职，自2026年4月起担任公司总裁兼首席执行官。Lamothe先生于2023年3月至2026年4月期间担任公司执行副总裁兼首席运营官，此前自2022年2月起担任执行副总裁兼首席财务官，此前自2016年7月起担任高级副总裁兼首席财务官。Lamothe先生此前曾担任Emergent生物科学部门财务副总裁。Lamothe先生于2014年2月在Emergent完成对Cangene Corporation（“Cangene”）的收购时担任这一职务，他在该公司担任首席财务官。Lamothe先生于2012年8月开始担任Cangene的首席财务官。在此之前，Lamothe先生是Smith Carter Architects and Engineers Incorporated的首席财务官，该职位于2010年1月至2012年7月担任。此前，他还在Kitchen Craft Cabinetry担任总裁兼首席执行官，此前他曾在该机构担任财务副总裁兼首席财务官。Lamothe先生过去的其他经验包括担任Motor Coach Industries的首席财务官，Lamothe先生曾在James Richardson父子有限公司和安永会计师事务所担任过不同职务。Lamothe先生在马尼托巴大学获得商业学士（荣誉）学位，是一名特许公共会计师。
- Jeffrey G. Lamothe has served on Aptevo Therapeutics Inc.'s Board and served as the President and Chief Executive Officer of the Company since April 2026. Mr. Lamothe served as the Company's Executive Vice President and Chief Operating Officer from March 2023 to April 2026, previously as Executive Vice President and Chief Financial Officer since February 2022 and previously as Senior Vice President and Chief Financial Officer since July 2016. Mr. Lamothe previously served as Emergent's Vice President Finance, Biosciences Division. Mr. Lamothe assumed this role in February 2014 when Emergent concluded the acquisition of Cangene Corporation ("Cangene"), where he was Chief Financial Officer. Mr. Lamothe assumed the role of Chief Financial Officer of Cangene in August 2012. Prior to that, Mr. Lamothe was the Chief Financial Officer for Smith Carter Architects and Engineers Incorporated, a position which he held from January 2010 until July 2012. He also previously served as President and Chief Executive Officer of Kitchen Craft Cabinetry after occupying the position of VP Finance and Chief Financial Officer with that organization. Mr. Lamothe's other past experience includes serving as Chief Financial Officer for Motor Coach Industries, and Mr. Lamothe has held various roles at James Richardson & Sons, Limited and Ernst & Young LLP. Mr. Lamothe earned his Bachelor of Commerce (honors) degree from the University of Manitoba and is a Chartered Public Accountant.
- SoYoung Kwon
SoYoung Kwon自2023年3月起担任Aptevo Therapeutics Inc.高级副总裁、总法律顾问、业务发展和公司事务，自2021年5月起担任高级副总裁、总法律顾问、公司事务和人力资源。权女士担任西雅图艺术博物馆的受托人和华盛顿奖学金基金会的总裁。她曾于2015年9月至2021年5月在AGC Biologics担任全球高级副总裁、总法律顾问和公司秘书，AGC Biologics是一家合同开发和制造组织，在美国、欧洲和亚洲设有工厂。权女士担任这一职务是在CMC Biologics于2016年12月被AGC Inc.收购后，她自2015年9月起担任副总裁、总法律顾问和公司秘书。在此之前，Kwon女士于2008年至2015年担任Onvia，Inc.的副总裁、总法律顾问和公司秘书。Kwon女士过去的其他经历包括担任Safeco Corporation的高级法律顾问和Graham & Dunn PC（现Miller Nash LLP）的企业助理。Kwon女士在华盛顿大学获得文学学士学位，在威拉米特大学法学院获得法学博士学位。
SoYoung Kwon has served as Aptevo Therapeutics Inc.'s Senior Vice President, General Counsel, Business Development and Corporate Affairs since March 2023, and Senior Vice President, General Counsel, Corporate Affairs and Human Resources since May 2021. Ms. Kwon serves as a Trustee of the Seattle Art Museum and President of the Washington Scholarship Foundation. She previously served as the Global Senior Vice President, General Counsel and Corporate Secretary at AGC Biologics, a contract development and manufacturing organization with facilities in the US, Europe and Asia from September 2015 to May 2021. Ms. Kwon assumed this role after CMC Biologics, where she was Vice President, General Counsel and Corporate Secretary since September 2015, was acquired by AGC Inc. in December 2016. Prior to that, Ms. Kwon was the Vice President, General Counsel and Corporate Secretary at Onvia, Inc. from 2008 to 2015. Ms. Kwon's other past experience includes serving as Senior Counsel at Safeco Corporation and a Corporate Associate at Graham & Dunn PC (now Miller Nash LLP).Ms. Kwon earned her Bachelor of Arts from the University of Washington and her Juris Doctorate from Willamette University College of Law.- SoYoung Kwon自2023年3月起担任Aptevo Therapeutics Inc.高级副总裁、总法律顾问、业务发展和公司事务，自2021年5月起担任高级副总裁、总法律顾问、公司事务和人力资源。权女士担任西雅图艺术博物馆的受托人和华盛顿奖学金基金会的总裁。她曾于2015年9月至2021年5月在AGC Biologics担任全球高级副总裁、总法律顾问和公司秘书，AGC Biologics是一家合同开发和制造组织，在美国、欧洲和亚洲设有工厂。权女士担任这一职务是在CMC Biologics于2016年12月被AGC Inc.收购后，她自2015年9月起担任副总裁、总法律顾问和公司秘书。在此之前，Kwon女士于2008年至2015年担任Onvia，Inc.的副总裁、总法律顾问和公司秘书。Kwon女士过去的其他经历包括担任Safeco Corporation的高级法律顾问和Graham & Dunn PC（现Miller Nash LLP）的企业助理。Kwon女士在华盛顿大学获得文学学士学位，在威拉米特大学法学院获得法学博士学位。
- SoYoung Kwon has served as Aptevo Therapeutics Inc.'s Senior Vice President, General Counsel, Business Development and Corporate Affairs since March 2023, and Senior Vice President, General Counsel, Corporate Affairs and Human Resources since May 2021. Ms. Kwon serves as a Trustee of the Seattle Art Museum and President of the Washington Scholarship Foundation. She previously served as the Global Senior Vice President, General Counsel and Corporate Secretary at AGC Biologics, a contract development and manufacturing organization with facilities in the US, Europe and Asia from September 2015 to May 2021. Ms. Kwon assumed this role after CMC Biologics, where she was Vice President, General Counsel and Corporate Secretary since September 2015, was acquired by AGC Inc. in December 2016. Prior to that, Ms. Kwon was the Vice President, General Counsel and Corporate Secretary at Onvia, Inc. from 2008 to 2015. Ms. Kwon's other past experience includes serving as Senior Counsel at Safeco Corporation and a Corporate Associate at Graham & Dunn PC (now Miller Nash LLP).Ms. Kwon earned her Bachelor of Arts from the University of Washington and her Juris Doctorate from Willamette University College of Law.
- Dirk Huebner
Dirk Huebner自2025年7月起担任Aptevo Therapeutics Inc.高级副总裁兼首席医疗官，自2022年4月起担任独立顾问的首席医疗官。Huebner先生在生物技术和制药领域拥有三十年的学术和行业临床药物开发经验。他领导Aptevo从早期研究到后期开发的临床策略和执行。此前，Dirk在Mersana（2018 – 2021）担任首席医疗官和高级医疗顾问，在那里他建立了临床开发部门并监督ADC管道。早些时候，作为波士顿生物医学的副总裁兼开发主管，他组建了一支强大的临床团队，并领导了多个早期项目，包括napabucasin 3期项目。在Millennium/Takeda Oncology，他担任ADCETRIS（brentuximab vedotin）的执行医疗主任和全球临床负责人，指导其欧洲监管批准和随后的注册授权研究。他还在Genzyme担任氯法拉滨治疗急性髓细胞白血病的临床负责人，并在罗氏和百时美施贵宝担任越来越重要的角色。德克拥有柏林弗雷大学的医学博士学位，并在Eppendorf（汉堡）大学医院泌尿外科完成了医学住院医师实习。
Dirk Huebner has served as Aptevo Therapeutics Inc.'s Senior Vice President and Chief Medical Officer since July 2025, and Chief Medical Officer as an independent consultant since April 2022. Mr. Huebner has three decades of academic and industry based clinical drug development experience across the biotech and pharmaceutical sectors. He leads Aptevo's clinical strategy and execution from early stage studies through late stage development. Previously, Dirk served as Chief Medical Officer and Senior Medical Advisor at Mersana (2018–2021), where he built the clinical development department and oversaw the ADC pipeline. Earlier, as Vice President and Head of Development at Boston Biomedical, he assembled a robust clinical team and led multiple early stage programs, including the napabucasin Phase 3 program. At Millennium/Takeda Oncology, he was Executive Medical Director and global clinical lead for ADCETRIS (brentuximab vedotin), guiding its European regulatory approval and subsequent registration enabling studies. He also served as clinical lead for clofarabine in acute myeloid leukemia at Genzyme and held roles of increasing responsibility at Roche and Bristol Myers Squibb. Dirk holds an M.D. from Freie Universitt Berlin and completed his medical residency at the Department of Urology, University Hospital Eppendorf (Hamburg).- Dirk Huebner自2025年7月起担任Aptevo Therapeutics Inc.高级副总裁兼首席医疗官，自2022年4月起担任独立顾问的首席医疗官。Huebner先生在生物技术和制药领域拥有三十年的学术和行业临床药物开发经验。他领导Aptevo从早期研究到后期开发的临床策略和执行。此前，Dirk在Mersana（2018 – 2021）担任首席医疗官和高级医疗顾问，在那里他建立了临床开发部门并监督ADC管道。早些时候，作为波士顿生物医学的副总裁兼开发主管，他组建了一支强大的临床团队，并领导了多个早期项目，包括napabucasin 3期项目。在Millennium/Takeda Oncology，他担任ADCETRIS（brentuximab vedotin）的执行医疗主任和全球临床负责人，指导其欧洲监管批准和随后的注册授权研究。他还在Genzyme担任氯法拉滨治疗急性髓细胞白血病的临床负责人，并在罗氏和百时美施贵宝担任越来越重要的角色。德克拥有柏林弗雷大学的医学博士学位，并在Eppendorf（汉堡）大学医院泌尿外科完成了医学住院医师实习。
- Dirk Huebner has served as Aptevo Therapeutics Inc.'s Senior Vice President and Chief Medical Officer since July 2025, and Chief Medical Officer as an independent consultant since April 2022. Mr. Huebner has three decades of academic and industry based clinical drug development experience across the biotech and pharmaceutical sectors. He leads Aptevo's clinical strategy and execution from early stage studies through late stage development. Previously, Dirk served as Chief Medical Officer and Senior Medical Advisor at Mersana (2018–2021), where he built the clinical development department and oversaw the ADC pipeline. Earlier, as Vice President and Head of Development at Boston Biomedical, he assembled a robust clinical team and led multiple early stage programs, including the napabucasin Phase 3 program. At Millennium/Takeda Oncology, he was Executive Medical Director and global clinical lead for ADCETRIS (brentuximab vedotin), guiding its European regulatory approval and subsequent registration enabling studies. He also served as clinical lead for clofarabine in acute myeloid leukemia at Genzyme and held roles of increasing responsibility at Roche and Bristol Myers Squibb. Dirk holds an M.D. from Freie Universitt Berlin and completed his medical residency at the Department of Urology, University Hospital Eppendorf (Hamburg).
- Mary Janatpour
Mary Janatpour自2026年5月起担任Aptevo Therapeutics Inc.的高级副总裁兼首席医疗官，负责监督利用公司专有技术开发癌症疗法的所有研发活动。Janatpour博士是一名肿瘤学研发主管和顾问，拥有超过35年的生物医学研究经验，其中包括超过25年帮助生物技术和制药公司通过战略性肿瘤管道开发建立价值。她领导了从靶点开始到1期临床研究的项目，在特定技术的最佳靶点选择和验证方面拥有特别的专业知识，包括抗体药物偶联物和新型药物模式。Janatpour博士还担任Active Motif的董事会成员，并且是Mithrl和Cypre的科学顾问。在加入Aptevo之前，Janatpour博士曾在Actym Therapeutics担任首席科学官，负责监督发现、临床前和转化工作，以推进其用于免疫肿瘤学和纤维化靶向原位药物递送的专有细菌系统。此前，她曾在Spotlight Therapeutics担任执行副总裁兼首席科学官，负责利用该公司专有的基于CRISPR的原位基因编辑平台，用于免疫肿瘤学和单基因疾病。在加入Spotlight之前，Janatpour博士曾在德纳维制药担任肿瘤学研究副总裁，在那里她领导了一个免疫肿瘤学临床项目和一个专注于与TLR激动剂合理临床组合的研究实验室。在她职业生涯的早期，她在Chiron Corporation、先灵葆雅生物制药公司和诺华公司建立了早期肿瘤生物制剂产品组合，并担任具有新平台的免疫肿瘤初创公司的独立顾问。Janatpour博士拥有加州大学伯克利分校的分子生物学学士学位和加州大学旧金山分校的生物医学科学博士学位，并在加州帕洛阿尔托的DNAX研究所完成了免疫学博士后培训。
Mary Janatpour has served as Aptevo Therapeutics Inc.'s Senior Vice President and Chief Medical Officer since May 2026, overseeing all research and development activities utilizing the Company's proprietary technologies to develop cancer therapeutics. Dr. Janatpour is an oncology research and development executive and advisor with more than 35 years of biomedical research experience, including more than 25 years helping biotechnology and pharmaceutical companies build value through strategic oncology pipeline development. She has led programs from target inception through Phase 1 clinical studies, with particular expertise in optimal target selection and validation for a given technology, including antibody drug conjugates and novel drug modalities. Dr. Janatpour also serves on the Board of Directors of Active Motif and is a scientific advisor to Mithrl and Cypre. Prior to joining Aptevo, Dr. Janatpour served as Chief Scientific Officer at Actym Therapeutics, where she oversaw discovery, preclinical and translational efforts to advance its proprietary bacterial system for targeted in situ drug delivery in immuno oncology and fibrosis. Previously, she served as Executive Vice President and Chief Scientific Officer at Spotlight Therapeutics, where she was responsible for leveraging the company's proprietary CRISPR based in situ gene editing platform for immuno oncology and monogenic diseases. Before Spotlight, Dr. Janatpour served as Vice President, Oncology Research at Dynavax Technologies, where she led an immuno oncology clinical program and a research laboratory focused on rational clinical combinations with TLR agonists. Earlier in her career, she built early stage oncology biologics portfolios at Chiron Corporation, Schering Plough Biopharma and Novartis, and served as an independent consultant to immuno oncology start ups with novel platforms. Dr. Janatpour holds a B.A. in Molecular Biology from the University of California, Berkeley and a Ph.D. in Biomedical Science from the University of California, San Francisco, and completed post doctoral training in immunology at the DNAX Research Institute in Palo Alto, California.- Mary Janatpour自2026年5月起担任Aptevo Therapeutics Inc.的高级副总裁兼首席医疗官，负责监督利用公司专有技术开发癌症疗法的所有研发活动。Janatpour博士是一名肿瘤学研发主管和顾问，拥有超过35年的生物医学研究经验，其中包括超过25年帮助生物技术和制药公司通过战略性肿瘤管道开发建立价值。她领导了从靶点开始到1期临床研究的项目，在特定技术的最佳靶点选择和验证方面拥有特别的专业知识，包括抗体药物偶联物和新型药物模式。Janatpour博士还担任Active Motif的董事会成员，并且是Mithrl和Cypre的科学顾问。在加入Aptevo之前，Janatpour博士曾在Actym Therapeutics担任首席科学官，负责监督发现、临床前和转化工作，以推进其用于免疫肿瘤学和纤维化靶向原位药物递送的专有细菌系统。此前，她曾在Spotlight Therapeutics担任执行副总裁兼首席科学官，负责利用该公司专有的基于CRISPR的原位基因编辑平台，用于免疫肿瘤学和单基因疾病。在加入Spotlight之前，Janatpour博士曾在德纳维制药担任肿瘤学研究副总裁，在那里她领导了一个免疫肿瘤学临床项目和一个专注于与TLR激动剂合理临床组合的研究实验室。在她职业生涯的早期，她在Chiron Corporation、先灵葆雅生物制药公司和诺华公司建立了早期肿瘤生物制剂产品组合，并担任具有新平台的免疫肿瘤初创公司的独立顾问。Janatpour博士拥有加州大学伯克利分校的分子生物学学士学位和加州大学旧金山分校的生物医学科学博士学位，并在加州帕洛阿尔托的DNAX研究所完成了免疫学博士后培训。
- Mary Janatpour has served as Aptevo Therapeutics Inc.'s Senior Vice President and Chief Medical Officer since May 2026, overseeing all research and development activities utilizing the Company's proprietary technologies to develop cancer therapeutics. Dr. Janatpour is an oncology research and development executive and advisor with more than 35 years of biomedical research experience, including more than 25 years helping biotechnology and pharmaceutical companies build value through strategic oncology pipeline development. She has led programs from target inception through Phase 1 clinical studies, with particular expertise in optimal target selection and validation for a given technology, including antibody drug conjugates and novel drug modalities. Dr. Janatpour also serves on the Board of Directors of Active Motif and is a scientific advisor to Mithrl and Cypre. Prior to joining Aptevo, Dr. Janatpour served as Chief Scientific Officer at Actym Therapeutics, where she oversaw discovery, preclinical and translational efforts to advance its proprietary bacterial system for targeted in situ drug delivery in immuno oncology and fibrosis. Previously, she served as Executive Vice President and Chief Scientific Officer at Spotlight Therapeutics, where she was responsible for leveraging the company's proprietary CRISPR based in situ gene editing platform for immuno oncology and monogenic diseases. Before Spotlight, Dr. Janatpour served as Vice President, Oncology Research at Dynavax Technologies, where she led an immuno oncology clinical program and a research laboratory focused on rational clinical combinations with TLR agonists. Earlier in her career, she built early stage oncology biologics portfolios at Chiron Corporation, Schering Plough Biopharma and Novartis, and served as an independent consultant to immuno oncology start ups with novel platforms. Dr. Janatpour holds a B.A. in Molecular Biology from the University of California, Berkeley and a Ph.D. in Biomedical Science from the University of California, San Francisco, and completed post doctoral training in immunology at the DNAX Research Institute in Palo Alto, California.
- Marvin L. White
Marvin L. White，目前担任董事的任期始于2020年10月。White先生曾担任Aptevo Therapeutics Inc.（“Aptevo”）的总裁兼首席执行官，并自2016年8月起担任其董事会成员。White先生于2010年6月首次担任Emergent的董事，直到2016年5月从Emergent董事会辞职。在加入Aptevo之前，他还曾担任Emergent的顾问。从2008年到2014年3月，White先生担任St. Vincent Health的首席财务官，负责所有19家医院和36家合资企业的财务、材料管理、会计、患者财务服务和管理式医疗。在2008年加入St. Vincent Health之前，White先生是Lilly USA（礼来公司的子公司）的首席财务官，他还曾在该公司的企业战略集团担任财务和企业融资以及投资银行方面的领导职务。怀特先生是OneAmerica Financial Insurance Partners，Inc.的董事，该公司是一家位于印第安纳州印第安纳波利斯的相互保险和金融服务公司，也是一家位于西雅图的牙科保险公司Delta Dental of Washington。从2014年6月到2016年8月，White先生在Washington Prime Group的董事会任职，这是一家投资于购物中心的NYSE REIT。从2015年7月到2017年3月，怀特先生在上市制药公司CoLucid Pharmaceuticals，Inc.的董事会任职。White先生获得了威尔伯福斯大学会计学学士学位和印第安纳大学金融硕士学位。
Marvin L. White has served as a member of Aptevo Therapeutics Inc.'s Board since August 2016 and served as Aptevo Therapeutics Inc.'s Executive Chair since April 2026. Mr. White served as Aptevo Therapeutics Inc.'s President and Chief Executive Officer from August 2016 to April 2026. From 2010 to 2016, Mr. White served as a director of Emergent, and in 2020, he rejoined the Emergent Board of Directors. From 2008 to 2014, Mr. White served as the Chief Financial Officer of St. Vincent Health, and was responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was the Chief Financial Officer of Lilly USA, LLC, a subsidiary of Eli Lilly and Company, where he also held leadership positions in treasury and corporate finance and investment banking in the Corporate Strategy Group. He serves on the Board of Directors of OneAmerica Financial Insurance Partners, Inc., a mutual insurance and financial services company based in Indianapolis, Indiana and Delta Dental of Washington, a non profit company. Prior to taking the role of President and Chief Executive Officer of Aptevo, Mr. White served on the Board of Directors of Washington Prime Group, a New York Stock Exchange listed real estate investment trust (REIT) that invests in shopping centers, and CoLucid Pharmaceuticals, Inc., a pharmaceutical company that was publicly traded until its acquisition by Eli Lilly in 2017. Mr. White earned a bachelor of science degree from Wilberforce University in Accounting and his MBA degree in Finance from Indiana University.- Marvin L. White，目前担任董事的任期始于2020年10月。White先生曾担任Aptevo Therapeutics Inc.（“Aptevo”）的总裁兼首席执行官，并自2016年8月起担任其董事会成员。White先生于2010年6月首次担任Emergent的董事，直到2016年5月从Emergent董事会辞职。在加入Aptevo之前，他还曾担任Emergent的顾问。从2008年到2014年3月，White先生担任St. Vincent Health的首席财务官，负责所有19家医院和36家合资企业的财务、材料管理、会计、患者财务服务和管理式医疗。在2008年加入St. Vincent Health之前，White先生是Lilly USA（礼来公司的子公司）的首席财务官，他还曾在该公司的企业战略集团担任财务和企业融资以及投资银行方面的领导职务。怀特先生是OneAmerica Financial Insurance Partners，Inc.的董事，该公司是一家位于印第安纳州印第安纳波利斯的相互保险和金融服务公司，也是一家位于西雅图的牙科保险公司Delta Dental of Washington。从2014年6月到2016年8月，White先生在Washington Prime Group的董事会任职，这是一家投资于购物中心的NYSE REIT。从2015年7月到2017年3月，怀特先生在上市制药公司CoLucid Pharmaceuticals，Inc.的董事会任职。White先生获得了威尔伯福斯大学会计学学士学位和印第安纳大学金融硕士学位。
- Marvin L. White has served as a member of Aptevo Therapeutics Inc.'s Board since August 2016 and served as Aptevo Therapeutics Inc.'s Executive Chair since April 2026. Mr. White served as Aptevo Therapeutics Inc.'s President and Chief Executive Officer from August 2016 to April 2026. From 2010 to 2016, Mr. White served as a director of Emergent, and in 2020, he rejoined the Emergent Board of Directors. From 2008 to 2014, Mr. White served as the Chief Financial Officer of St. Vincent Health, and was responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was the Chief Financial Officer of Lilly USA, LLC, a subsidiary of Eli Lilly and Company, where he also held leadership positions in treasury and corporate finance and investment banking in the Corporate Strategy Group. He serves on the Board of Directors of OneAmerica Financial Insurance Partners, Inc., a mutual insurance and financial services company based in Indianapolis, Indiana and Delta Dental of Washington, a non profit company. Prior to taking the role of President and Chief Executive Officer of Aptevo, Mr. White served on the Board of Directors of Washington Prime Group, a New York Stock Exchange listed real estate investment trust (REIT) that invests in shopping centers, and CoLucid Pharmaceuticals, Inc., a pharmaceutical company that was publicly traded until its acquisition by Eli Lilly in 2017. Mr. White earned a bachelor of science degree from Wilberforce University in Accounting and his MBA degree in Finance from Indiana University.
- Daphne Taylor
Daphne Taylor，2011年8月以来一直是金融和管理副总裁、首席财务官，自2013年1月30日担任秘书。从2011年3月到2011年7月她担任公司的总监。在加入公司之前，她从2005年11月到2009年1月担任心脏科学公司的副总裁、企业总监和首席财务官。从2002年4月到2005年11月她担任不同职位，包括LookSmart公司副总裁和公司总监。
Daphne Taylor has served as Aptevo Therapeutics Inc.'s Senior Vice President, Chief Financial Officer since March 2023 and previously served as Aptevo's Senior Vice President of Finance where she held responsibility for all strategic planning and budgeting, treasury activities, internal and external reporting, and financial compliance since May 2016. Prior to Aptevo, Ms. Taylor's career includes 25 years of financial experience in the life sciences and technology industries. Prior to joining Aptevo, Ms. Taylor served as Chief Financial Officer at BioLife Solutions. She also served as VP, Chief Accounting Officer, and Controller at Cardiac Science Corporation and in multiple other roles, including Controller at LookSmart, SpeedTrak, CoreMark International and Pacific Telesis. Ms. Taylor began her career at Coopers & Lybrand in San Francisco. She is active in her community and serves on the Finance Committee of the Northshore Schools Foundation. Ms. Taylor holds a Bachelor of Arts from Sonoma State University and is a Licensed CPA in Washington and California.- Daphne Taylor，2011年8月以来一直是金融和管理副总裁、首席财务官，自2013年1月30日担任秘书。从2011年3月到2011年7月她担任公司的总监。在加入公司之前，她从2005年11月到2009年1月担任心脏科学公司的副总裁、企业总监和首席财务官。从2002年4月到2005年11月她担任不同职位，包括LookSmart公司副总裁和公司总监。
- Daphne Taylor has served as Aptevo Therapeutics Inc.'s Senior Vice President, Chief Financial Officer since March 2023 and previously served as Aptevo's Senior Vice President of Finance where she held responsibility for all strategic planning and budgeting, treasury activities, internal and external reporting, and financial compliance since May 2016. Prior to Aptevo, Ms. Taylor's career includes 25 years of financial experience in the life sciences and technology industries. Prior to joining Aptevo, Ms. Taylor served as Chief Financial Officer at BioLife Solutions. She also served as VP, Chief Accounting Officer, and Controller at Cardiac Science Corporation and in multiple other roles, including Controller at LookSmart, SpeedTrak, CoreMark International and Pacific Telesis. Ms. Taylor began her career at Coopers & Lybrand in San Francisco. She is active in her community and serves on the Finance Committee of the Northshore Schools Foundation. Ms. Taylor holds a Bachelor of Arts from Sonoma State University and is a Licensed CPA in Washington and California.